To view Orionis Biosciences’s complete valuation and funding history, request access », To view Orionis Biosciences’s complete executive team members history, request access », To view Orionis Biosciences’s complete board members history, request access », To view Orionis Biosciences’s complete investors history, request access », Co-Founder, Chief Executive Officer, President & Board Member. Developer of precision drugs and medical equipment designed to focus on new strategies to combat cancer. PitchBook is a financial technology company that provides data on the capital markets. US Office. Consisting of an instrument, consumables, software, and assays, it enables scientists to create libraries of millions of precisely engineered single cells in one experiment through a fully automated workflow. Paladin Capital Group led the round, bringing the total amount raised by the company to $259.5 million. BOSTON & GHENT, Belgium--(BUSINESS WIRE)--Orionis Biosciences is today debuting with the announcement of a major drug discovery collaboration with Novartis. Riccardo Sabatini, PhD, CDS, joined the company as architect and leader of Orionis’ computational science platform. Orionis was originally founded by drug discovery and technology pioneers Niko Kley, PhD, CEO, Jan Tavernier, PhD, CTO and Professor at VIB-Ghent University (Belgium), and VIB. Orionis Biosciences . Proceeds of the financing are intended to be used in part to expand the ArcherDX global commercial footprint, support the registration and launch of the STRATAFIDE pan-solid tumor companion diagnostic (CDx) and, in concert with ongoing biopharma collaborations, to support development of ArcherDX’s Personalized Cancer Monitoring (PCM) platform. We maintain the highest ethical, moral and legal standards. Despite widespread antimicrobial resistance and the dramatic progress in genomics and computational biology, development efforts for new antimicrobials are declining worldwide. Companies People Investors Funding Rounds Acquisitions Schools Events Hubs Saved . 3 results Search. Pat Smerkers of Northpond has joined the Board of Directors. Employs a multidisciplinary group of researchers with expertise in bioinformatics, microbiology and artificial intelligence. Orionis Biosciences has research facilities in the Boston area (Headquarters in Waltham, MA, USA) and Ghent (Belgium), and is operated by a world class team of entrepreneurs, scientists and transatlantic network of investors, in concert with strategic research and development collaborations. TwinStrand Biosciences, Seattle, Wash., announced the close of $16 million in Series A funding, including $12 million in new capital. Is to address and solve health, trade and security challenges, To Monitor and Track Known and Unknown Biothreats. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, Biotechnology Companies with Early Stage Venture Funding, Northeastern US Health Care Companies with Early Stage Venture Funding. E.g. Crunchbase, Slack, Lyft. Save Search . Duplex Sequencing identifies extremely rare mutations that go undetected by current next-generation sequencing (NGS) platforms. Orionis Biosciences is today debuting with the announcement of a major drug discovery collaboration with Novartis. Bridge Connector, Nashville, Tenn., offers data-driven workflow automation to solve health IT interoperability challenges. Proceeds from the financing will be used to accelerate development of novel HDPCR products for digital PCR and real-time PCR platforms; expand partnerships with leading companies in molecular infectious disease, reproductive health and precision medicine for oncology; and support commercialization of ChromaCode's new multiplexed products for multi-drug resistance and tick-borne pathogens. The PXV Fund complements Perceptive Advisors’ Life Sciences Master and Credit Opportunities Funds as it will be solely focused on early-stage venture capital and expects to be the sole or predominant lead investor in Series A rounds in the range of $10-20 million with capacity to participate in subsequent Series B rounds. Our hope is that through this collaboration, we will be able to reach historically elusive targets as we strive to bring new therapies to patients more quickly.”, Riccardo Sabatini commented further, “It is incredibly exciting to see how mapping of genome-scale fingerprints of drug action is opening new possibilities and dimensions in applications of numerical methods and machine learning to support drug design.”. Read more about Verantos: How Accurate Are Real World Data? This innovative biotechnology company was founded with the help of a consortium of international investors. $125M: Series D, Digital Genome Engineering Platform. The goal of the four-year collaboration is to discover and design novel small molecule therapeutics, such as protein degraders, across various therapeutic areas, by broadly leveraging Orionis’ Allo-Glue technology … The additional financing will support Bridge Connector’s continued scalability and its upcoming launch of Destinations, a new integration platform as a service (iPaaS) that connects health data systems without the need for code. $4,025,000. In April the Flemish Institute for Biotechnology (VIB) and the University of Ghent announced the launch of Orionis Biosciences, a start-up specialised in the development of new drugs for the treatment of certain autoimmune diseases and pathologies linked to certain types of cancer. The company's drugs and equipment are tested various times with pioneering technology innovation in genome-scale drug discovery and tunable molecular design of novel therapeutic drug modalities, enabling people to get advance … Unlike current centralized testing, STRATAFIDE allows tissue and blood samples to be analyzed at any local lab with a sequencer, thereby enabling faster turnaround times, while providing physicians with critical information needed to deliver targeted, personalized care. Orionis Biosciences Inc 950 Winter Street Waltham, MA 02451. Read more about Deep Genomics: Deep Genomics Identifies Rare Disease Targets Using AI System and Causation in Context: Brendan Frey's Vision for Deep Genomics, $28M: Series C, Digital and Real-Time PCR. Orionis Biosciences is a life sciences company pioneering technological innovation in genome-scale drug discovery and tunable molecular design of novel therapeutic drug modalities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echnology Square, 5th Floor Cambridge, MA 02139 617.674.5100 See insights on Orionis Biosciences including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. According to Orionis, the deal involves research funding, a convertible note investment, royalties and also clinical milestones. Orionis Biosciences is a life sciences company pioneering technological innovation in genome-scale drug discovery and tunable molecular design of novel therapeutic drug modalities. Companies People Investors Funding Rounds Acquisitions Schools Events Hubs Saved . “We have quietly built and evolved our core science capabilities, portfolio of intellectual property and an exciting emerging pipeline of drug candidates, which we are advancing to unlock major value for the pharmaceutical industry and new treatment options for patients in need,” commented CEO Niko Kley. The latter includes collaborations with VIB (Belgium), Orionis Biosciences co-founding institution. We have a strong sense of urgency to get things done quickly and efficiently. TwinStrand Biosciences, Seattle, Wash., announced the close of $16 million in Series A funding, including $12 million in new capital. Our technologies and pipeline include proprietary A-Kine™ biologics and Allo-Glue™ small molecule platforms with broad, innovative applications to the reprogramming of disease states. Company Type For Profit. The company plans to advance two programs to IND in 2020 and obtain Phase 1/2 data for its Wilson disease candidate in 2021. $55M: Series C, Actionable Genomic Alterations In Tissue Or Blood. The PXV Fund will be focused exclusively on life sciences technologies across therapeutic areas with a greater emphasis on drug technologies and less focus on early drug and platform discovery. They act to alter the form and function of, and thereby reprogram, intracellular proteins to engage in molecular interactions that modulate disease target proteins, including promoting their degradation by a cell’s natural protein disposal machinery. List of Orionis Biosciences 's 3 Funding Rounds totaling $23.7M. [])), +((!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+!![]+[])+(!+[]+(!![])+!![]+!![]+!![])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+!![])+(!+[]+(!![])+!![]+!![]+!![])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+!![]+!![])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+!![]+!![])+(!+[]+(!![])+!![]+!![]+!![])+(!+[]-(!![]))+(!+[]+(!![])+!![]))/+((!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+[])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+!![]+!![])+(!+[]-(!![]))+(!+[]+(!![])+!![])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+!![])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+!![])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!! Click here to login and The approach results in remarkable clarity and speed: 70% of research projects have led to therapeutic leads, and programs have been taken from target discovery to drug candidate in less than 12 months. Our proprietary genome-wide discovery and drug design technologies may enable identification and development of small molecules and biologics with high specificity and selectivity against targets at a scale, speed and efficiency that is unique in the industry.”.